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Abstract
Introduction: Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for
hyperglycemic patients is still controversial. This study examines whether a high-protein diabetes-specific formula
reduces insulin needs, improves glycemic control and reduces ICU-acquired infection in critically ill, hyperglycemic
patients on mechanical ventilation (MV).
Methods: This was a prospective, open-label, randomized (web-based, blinded) study conducted at nine Spanish
ICUs. The patient groups established according to the high-protein formula received were: group A, new-
generation diabetes-specific formula; group B, standard control formula; group C, control diabetes-specific formula.
Inclusion criteria were: expected enteral nutrition ≥5 days, MV, baseline glucose >126 mg/dL on admission or >200
mg/dL in the first 48 h. Exclusion criteria were: APACHE II ≤10, insulin-dependent diabetes, renal or hepatic failure,
treatment with corticosteroids, immunosuppressants or lipid-lowering drugs and body mass index ≥40 kg/m2. The
targeted glucose level was 110–150 mg/dL. Glycemic variability was calculated as the standard deviation, glycemic
lability index and coefficient of variation. Acquired infections were recorded using published consensus criteria for
critically ill patients. Data analysis was on an intention-to-treat basis.
Results: Over a 2-year period, 157 patients were consecutively enrolled (A 52, B 53 and C 52). Compared with the
standard control formula, the new formula gave rise to lower insulin requirement (19.1 ± 13.1 vs. 23.7 ± 40.1 IU/day,
p <0.05), plasma glucose (138.6 ± 39.1 vs. 146.1 ± 49.9 mg/dL, p <0.01) and capillary blood glucose (146.1 ± 45.8 vs.
155.3 ± 63.6 mg/dL, p <0.001). Compared with the control diabetes-specific formula, only capillary glucose levels
were significantly reduced (146.1 ± 45.8 vs. 150.1 ± 41.9, p <0.01). Both specific formulas reduced capillary glucose
on ICU day 1 (p <0.01), glucose variability in the first week (p <0.05), and incidences of ventilator-associated
tracheobronchitis (p <0.01) or pneumonia (p <0.05) compared with the standard formula. No effects of the nutrition
formula were produced on hospital stay or mortality.
Conclusions: In these high-risk ICU patients, both diabetes-specific formulas lowered insulin requirements,
improved glycemic control and reduced the risk of acquired infections relative to the standard formula. Compared
with the control-specific formula, the new-generation formula also improved capillary glycemia.
Trial registration: Clinicaltrials.gov NCT1233726.
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Introduction
Critically ill patients show a stereotype metabolic response
to injury that affects carbohydrate metabolism [1, 2], caus-
ing hyperglycemia, which is boosted by the actions of
counterregulatory hormones [3, 4]. This metabolic re-
sponse makes the critically ill patient especially susceptible
to infection and increases morbidity and mortality [5–7].
The control of blood glucose levels and adequate nutri-
tional support contribute to metabolic improvement and
help reduce the risk of infection.
Glycemic variability (GV) has been independently
associated with mortality and a higher risk of intensive
care unit (ICU)-acquired infection in critically ill pa-
tients [8–11]. Accordingly, it has been proposed that this
variability could be improved by modifying the compos-
ition of the standard enteral nutrition formula given to
the patient [12]. In an effort to avoid the detrimental
consequences of hypoglycemia [13–15], many ICUs have
elevated their targeted lower limits for glucose levels.
However, to date no consensus has been reached on the
optimal target glucose range [16–19].
Hyperglycemia in the ICU patient can be treated with
exogenous insulin [20, 21] and by the enteral administra-
tion of diabetes-specific formulas [22]. Although the use
of standard enteral nutrition (EN) products is widely
accepted, the benefits of disease-specific or modified
standard enteral formulas for hospitalized patients with
diabetes remain controversial [23, 24]. When used as
short- to medium-term treatment, a standard high-
carbohydrate/low-fat diet may compromise glycemic con-
trol [25, 26]. By modifying carbohydrate composition and
adding monounsaturated fatty acids (MUFA) and fiber,
studies have shown improved glycemic control compared
with a standard diet [27–29]. However, few studies have
examined the benefits of diabetes-specific formulas in crit-
ically ill patients with hyperglycemia [30].
We hypothesized that in the hyperglycemic, critically ill
patient, the use of a diabetes-specific nutrition formula
might serve to improve glycemic control and reduce the
risk of hospital-acquired infection. The aim of our study
was to compare, in mechanically ventilated ICU patients
with hyperglycemia, the use of three EN formulas: a
standard EN formula, a widely used diabetes-specific for-
mula and a new-generation diabetes-specific formula. This
last formula contains high protein levels, MUFA, slowly
absorbed carbohydrates, and omega-3 polyunsaturated
fatty acids (PUFA), and is enriched with eicosapentaenoic
acid (EPA), docosahexaenoic acid (DHA) and fiber.
Methods
Study design and data collection
A prospective, multicenter, open-label, blind-randomized,
controlled clinical trial was conducted in medical-surgical
ICUs in nine teaching hospitals in Spain. The study
protocol was approved by each hospital’s review board. A
list of ethics committees that approved the study at each
institution is provided as Additional file 1. Written
informed consent was obtained from participating patients
or closest relatives.
The primary endpoint was the amount of insulin re-
quired to keep glucose levels in the range 110–150 mg/
dL (glycemia target). Secondary endpoints were glycemic
control (plasma and capillary blood glucose, glycemic
variability), ICU-acquired infection (catheter-related
bloodstream infection, primary bloodstream infection,
urinary tract infection, ventilator-associated tracheo-
bronchitis incidence rate/1000 ventilator days and
ventilator-associated pneumonia incidence rate/1000
ventilator days), days on mechanical ventilation (MV),
ICU stay and mortality at 28 days post admission. After
ICU discharge, patients were followed for 6 months to
record hospital stay, hospital mortality, and 6-month
mortality.
Patient assignment/randomization
The study was performed over the period April 2010 to
May 2012. A website was constructed to record data and
to randomize patients to each EN formula. Data were
collected online using an electronic case report form.
For randomization, the website assigned the formulas
in a blinded, centralized fashion in blocks of six pa-
tients, including at least three blocks stratified by par-
ticipating center, according to the sequence: study
group A, new-generation diabetes-specific high-protein
formula (Diaba HP®, Vegenat, Badajoz, Spain); control
group B, standard high-protein formula (Isosource Pro-
tein Fibra®, Nestlé Health Science, Barcelona, Spain);
control group C, widely used diabetes-specific high-
protein formula (Glucerna Select®, Abbott Nutrition,
Madrid, Spain). Patients were consecutively enrolled at
each center by the responsible researcher. When enrol-
ling a patient, the researcher was blind to the
randomization sequence. All participants were followed
at the ICU for a maximum of 28 days.
Patient eligibility
Inclusion criteria were: age ≥18 years, ICU stay ≤48
hours upon randomization to EN formula, mechanical
ventilation, EN indicated for an expected time ≥5 days.
Patients were also required to meet American Diabetes
Association criteria for diabetes/hyperglycemia [31]
(baseline blood glucose >126 mg/dL after fasting or
>200 mg/dL otherwise) in the first 48 h of ICU admis-
sion. Exclusion criteria were: contraindication for EN,
expected EN <5 days, Acute Physiology and Chronic
Health Evaluation II (APACHE II) score ≤10, insulin-
dependent diabetes, acute or chronic kidney failure
[32], liver failure (total bilirubin ≥3 mg/dL, Child-Pugh
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B-C), life expectancy ≤48 h, previous cardiac arrest,
long-term therapy with corticosteroid, immunosuppres-
sant or lipid-lowering drugs, pregnancy, body mass
index (BMI) ≥40 and parenteral nutrition (PN).
Administration protocol and formula composition
The study patients were started on EN through a nasogas-
tric tube within 48 h of ICU admission. Enteral feeding
was continued over 24 h each day and only interrupted
for 8 h (from 12 p.m. to 8 a.m.) along with insulin infusion
on days 3, 7, 14, 21 and 28 to obtain samples for complete
blood tests. Patients were managed by the responsible re-
searchers at each center. Gastric residual volume (GRV)
was measured every 6 h for the first 2 days and every 24 h
thereafter until EN was stopped. All patients received 10
mg metoclopramide every 8 h only for the first 3 days.
Prescribed caloric intake was 25 kcal/kg/day. Nutritional
requirements were calculated by the responsible re-
searchers. It was ensured that patients received their
calculated requirements in the first 48 h of EN. Non-
nutritional caloric constituents like glucose or propofol
were included in caloric balance calculations. Insulin was
administered in saline solution at a 1:1 ratio by continuous
infusion using a 50-mL syringe pump. The nursing staff
adjusted the dose guided by capillary blood glucose levels
using a sliding-scale algorithm and a point-of-care glucose
meter following a consensus protocol for the nine partici-
pating centers (see Table S1 in Additional file 2).
Patients were randomized to receive one of three dif-
ferent nutrition formulas (Table 1). The two diabetes-
specific formulas contain greater percentages of fat while
the standard formula has a greater carbohydrate content
and less fiber. The carbohydrates included in each for-
mula are: low-dextrose-equivalent maltodextrin and type
IV-resistant maltodextrin in the study formula; modified
maltodextrin, fructose and maltitol in the control
diabetes-specific formula; and maltodextrin and sacchar-
ose in the standard high-protein formula. The two spe-
cific formulas contain greater proportions of MUFA and
the study diet also has higher ω-3, EPA and DHA con-
tents. Due to their different caloric densities, formula
volumes were calculated on the website to ensure pa-
tients received similar caloric and nitrogenous support.
Variables and controls
Baseline data were collected before starting EN (Table 2).
Both the Sequential Organ Failure Assessment (SOFA)
and Homeostasis Model Assessment (HOMA2) [33]
were repeated on days 3, 7, 14, 21 and 28 after ICU
admission.
Variables were monitored for a maximum of 28 days.
The variables MV days, EN days and ICU stay were
recorded when the patient was discharged from the
ICU. Hospital stay and mortality were recorded at 28
days and 6 months.
Complete blood tests were conducted on a peripheral
blood sample on ICU admission. Blood samples for simi-
lar tests on days 3, 7, 14, 21 and 28 post admission were
obtained at 8 a.m., 8 hours after stopping EN and insulin
infusion.
The glycemic target was set at 110–150 mg/dL. For the
present purposes, severe hypoglycemia was defined as a
blood glucose level less than 50 mg/dL and moderate
hypoglycemia as a level of 50–80 mg/dL. Insulin infusion
was started when glucose levels reached ≥150 mg/dL. To
monitor daily plasma glucose levels, venous blood was
withdrawn from each patient at 8 a.m.; capillary blood
glucose levels were monitored every 1–4 h using a Gluc-
ometer Elite XL from Bayer®, Barcelona, Spain. Plasma
glucose levels were measured by the hexokinase method
at each center’s main laboratory.
In each patient, we recorded mean and standard devi-
ation (SD) plasma glucose levels. Daily mean (GluM) and
standard deviation (GluSD) capillary blood glucose levels
were obtained during their ICU stay. Insulin (in inter-
national units) administered to each patient per day was
also recorded.
The following glycemia control indices were recorded
for each patient [8]: plasma glucose level on admission;
mean and SD of capillary blood glucose levels recorded
on ICU day 1; peak glucose during ICU stay; and GV
during the first 7 days and during the 28 days of the
study. Glycemic variability was measured as the mean
SD of daily capillary glucose levels, the coefficient of
variation (CV) according to the equation GluCV =
GluSD × 100/GluM, and the glycemic lability index (GLI).
The GLI was calculated using the Ryan equation [34]
modified for critically ill patients and corrected for the













where Glucn is the nth reading for the patient at time
n measured in mmol/L, N is the total number of read-
ings performed that day, and hn is the time in hours of
the nth reading at time n.
Patients were examined daily to detect the presence of
gastrointestinal complications. The following gastro-
intestinal complications were defined according to cri-
teria published by our group [35, 36]:
a) Abdominal distention: tympany and/or absence of
bowel sounds; b) high GRV: recovered gastric volume
equal to or greater than 500 mL; c) vomiting: enteral for-
mula ejected through the mouth; d) diet regurgitation:
enteral formula found in oral or nasal cavities with or
without exteriorization; e) diarrhea: five or more liquid
Mesejo et al. Critical Care  (2015) 19:390 Page 3 of 13
Table 1 Composition of enteral formulas per 100 kcal and per 100 ml
Nutritional information DIABA HP® ISOSOURCE PROTEIN FIBRA® GLUCERNA SELECT®
Caloric density (kcal : ml) 1 : 1 1.4 : 1 1 : 1
Energy/volume Per 100 kcal / per 100 ml Per 100 kcal / per 100 ml Per 100 kcal / per 100 ml
Protein (g) 5.7 5.00 / 7.00 5.00
Casein 50 % Casein 100 % Casein 80 %
Whey P + GMP 25 % Soy P 20 %
Vegetable P 25 %
Carbohydrates (g) 8.2 10.93/15.3 7.46
Modified maltodextrin
(low dextrose equivalent and type IV resistant)
Standard maltodextrin Modified maltodextrin
Sucrose Fructose
Maltitol
Fat (g) 4.4 3.79 / 5.3 5.44
Saturated (g) 1.1 1.00 / 1.4 0.45
Monounsaturated (g) 2.2 1.43 / 2 3.58
Polyunsaturated (g) 1.00 1.37 / 1.92 1.14
EPA + DHA (mg) 67.6 - -
Fiber (g) 1.8 1.07 / 1.5 1.44
Soluble 1.4 0.5 / 0.7 0.21
Insoluble 0.4 0.57 / 0.8 1.23
Minerals
Calcium (mg) 80 53.5 / 75 70
Phosphate (mg) 75 53.5 / 75 65
Potassium (mg) 200 96.4 / 135 130
Sodium (mg) 70 60.7 / 85 94
Chlorine (mg) 70 107.1 / 150 125
Iron (mg) 1.1 0.79 / 1.1 1.3
Zinc (mg) 1.1 0.79 / 1.1 1.2
Copper (μg) 113 0.10 / 0.14 140
Iodine (μg) 10 8.57 / 12 11
Selenium (μg) 4.8 3.29 / 4.6 5
Magnesium (mg) 16 15.71 / 22 21
Manganese (mg) 0.15 0.16 / 0.22 0.35
Fluoride (mg) 0.12 0.11 / 0.16 0
Molybdenum (μg) 4.4 4.14 / 5.8 10
Chromium (μg) 2 2.86 / 4 8.5
Vitamins
A (μg) 85 57.14 / 80 58
D (μg) 1.3 0.71 / 1 0.93
E (mg) 1.5 1.14 / 1.6 1.9
C (mg) 9.1 3.57 / 5 11
B1 (mg) 0.22 0.09 / 0.12 0.15
B2 (mg) 0.22 0.11 / 0.16 0.18
B3 (mg) 1.5 1.29 / 1.8 1.7
B6 (mg) 0.22 0.11 / 0.16 0.21
B9 (mg) 27 14.29 / 20 25
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stools in a 24-h period or an estimated stool volume
equal or greater than 2000 mL/day.
If a complication required withholding the diet for >48
h or starting PN, the case was closed but included in the
intent-to-treat analysis.
The volume ratio (VR) was estimated as a measure of
the efficacy of daily nutritional administration and calcu-
lated as follows: VR (%) = (volume administered/volume
prescribed) × 100. Also calculated were calorie and nutri-
ent (carbohydrates, fats and proteins) intakes per
patient/day based on daily infused volumes and formula
composition.
ICU-acquired infections were defined according to cri-
teria for critically ill patients emerging from consensus
conferences [37, 38]. An infection was recorded as ac-
quired if starting 48 h after ICU admission. Biological
samples for microbiological cultures were obtained when
there was clinical suspicion of infection or at least once
a week. The following variables were recorded: number
of infected patients, infection rate/100 days of ICU stay,
Table 1 Composition of enteral formulas per 100 kcal and per 100 ml (Continued)
B12 (μg) 0.32 0.26 / 0.36 0.3
Biotin (μg) 4 7.29 / 10.2 4
Pantothenic A. (mg) 0.8 0.31 / 0.44 0.75
K (μg) 5.2 5.71 / 8 10
Choline (μg) 37 - 43
Osmolarity (mOsm/L) 345 399 378
Pprotein, GMP glycomacropeptide, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, A acid
Table 2 Demographics and baseline clinical characteristics of the study population
VARIABLE GROUP A GROUP B GROUP C
(n = 52) (n = 53) (n = 52)
Age (years) 57 (43–70) 60 (45–71) 58 (46–68)
Male (N and %) 37 (71.1 %) 43 (81.1 %) 39 (75 %)
BMI (kg/m2) 26 (24–29) 26 (24–28) 26 (24–27)
APACHE II 17 (14–23) 19 (15–22) 19 (16–23)
SOFA score 8 (6–14) 7 (5–12) 7 (4–12)
Calorie requirements (kcal/day) 1690.4 (384.9) 1707.1 (275.4) 1728.2 (309.2)
Start of EN (hours) 23.4(18.1-27.2) 25.1 (19.6-26.2) 26.7 (21.3-28)
Noninsulin-dependent diabetes (N and %) 11 (21.1 %) 7 (13.2 %) 12 (23 %)
HbA1c (%) 6.34 (1.38) 5.76 (0.95) 6.07 (1.39)
Capillary glucose level (mg/dL)a 148.8 (38.8) 149.9 (38.9) 151.5 (39.23)
Plasma glucose level (mg/dL)a 152.1 (54.6) 147.01 (55.93) 152.1 (57.12)
Insulinemia (μU/mL)a 21.59 (36.06) 17.39 (23.77) 19.15 (20.5)
C-peptide (ng/mL)a 4.61 (3.24) 4.49 (2.92) 4.27 (3.67)
HOMA2 IR 2.94 (4.19) 2.48 (2.76) 3.38 (2.37)
HOMA2 %B (β-cell) 102.6 (57.81) 110.5 (74.34) 96.55 (85.09)
HOMA2 %S 79.12 (75.2) 69.6 (48.7) 68.09 (66.9)
Infection (any source) (N and %) 13 (25 %) 15 (28.3 %) 8 (15.3 %)
Diagnostic group (N and %)
Medical 32 (61.53 %) 36 (67.93 %) 30 (57.69 %)
Trauma 13 (25 %) 9 (16.98 %) 15 (28.85 %)
Surgery 7 (13.47 %) 8 (15.09 %) 7 (13.46 %)
Values are provided as mean (SD), median (Q1-Q3) and percentages (%)
N number, BMI body mass index, APACHE II, Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, EN enteral nutrition,
HbA1c glycated hemoglobin, HOMA2 Homeostasis Model Assessment, IR insulin resistance, %S insulin sensitivity, %B beta cell functionaMeasured after fasting and
without insulin infusion for at least 8 hours
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tracheobronchitis/1000 days of MV, ventilator-associated
pneumonia/1000 days of MV, bacteremia and urinary
tract infection.
Power calculations and data treatment
Based on the results of our previous study [30], an insu-
lin requirement reduction of at least 20 % was consid-
ered clinically meaningful. Assuming an α risk of 0.05
and a β risk of 0.20 (power = 80 %), the required number
of patients was estimated at 159. Each case was recorded
in the electronic logbook by the responsible researcher,
sent to the principal investigators for verification, and
entered into a central database. Each case was checked
to ensure that the patient met the inclusion/exclusion
criteria, the study protocol had been adequately followed
and all the required data had been provided. Discrepan-
cies and transcription errors were discussed among the
researchers and clarified by the principal investigators.
An intent-to-treat analysis was performed. Qualitative
variables are expressed as absolute and relative frequen-
cies and continuous variables as means (±SD) or as me-
dians (quartile 1; quartile 3). Qualitative variables were
compared using the chi-squared test or Fisher’s exact test.
Continuous data were assessed for normality using the
Kolmogorov-Smirnov test. The nonparametric Kruskal-
Wallis and Mann-Whitney U tests were used when the
data did not fit the assumptions of normality. If the
dependent variable under examination was quantitative,
we statistically assessed the comparability of the three
treatment groups by one-way analysis of variance
(ANOVA) and the corresponding multiple comparison
of means test (Tukey’s HSD, Bonferroni). For the main
outcome measures, a repeated measures generalized
linear model (GLM) was used when considering mea-
surements taken at different time points in a single
patient.
For incidence rates, we used inference methods on
variables recorded in two populations, obtaining a p
value for the chi-squared test. The relationship between
glucose variability and acquired infection complication
rate adjusted for time was calculated using the linear
correlation coefficient (Pearson’s r test).
All statistical tests were performed using the SAS stat-
istical analysis system package (version 9.3, SAS Insti-
tute, Cary, NC, USA) SPSS (version 21, IBM Corp.,
Armonk, NY, USA) and the epidemiological analysis
program EPIDAT for tabulated data (version 3.1, Epi-
Data Association, Odense, Denmark). Significance was
set at p <0.05.
Results
Baseline characteristics
A total of 159 consecutive ICU patients fulfilling the
inclusion criteria were initially recruited. Two patients
were excluded because of incorrect randomization (one
group A, one group C) leaving a study population of 157
patients (52 group A, 53 group B, 52 group C) (Fig. 1).
Fifteen patients did not complete the minimum of 5 days
of treatment, but all 157 were included in the intent-to-
treat analysis. The three patient groups were homoge-
neous in terms of demographic and baseline clinical
characteristics (Table 2).
Nutrition onset was targeted for within 24 h of ICU
admission. Median values for EN onset after ICU admis-
sion in hours were 23.4 (18.1–27.2), 25.1 (19.6–26.2)
and 26.7 (21.3–28) for groups A, B and C, respectively
(Table 2).
The calorie and protein intake values provided in
Table 3 indicate isocaloric and isonitrogenous intakes
across the three groups, with no differences in effective
volume. The mean volume ratio was approximately 80 %
of the prescribed ratio. Despite differences in fiber,
carbohydrate and lipid intake arising from the different
formula compositions, total intakes were within recom-
mended limits. Propofol 2 % was administered in the
first 7 days of ICU stay in six group A, seven group B,
and five group C patients. The maximum dose received
by these patients was 2.2 g/d and the kcal provided by
this agent was included in the calorie intake calculations.
The intravenous administration of glucose 5 % in three
group A, two group B and two group C patients some
time during their ICU stay was also taken into account
as a source of calories.
Glycemic and metabolic control
The variables recorded related to glycemic control are
provided in Table 4. These data indicate that patients in
group A needed less insulin (p <0.05) and showed lower
plasma and capillary blood glucose levels than those in
group B (p <0.01 and p <0.001 respectively). No differ-
ences were detected in insulin dose between groups A
and C; however, in the group A patients, capillary blood
glucose was significantly lower (p <0.01). Both diabetes
formulas achieved significant improvements in mean ca-
pillary glycemia (MCG) on the first day of ICU stay
compared with group B (p <0.01). No differences
emerged among the three groups in peak glycemia,
number of capillary glycemia measurements and number
of measurements made per patient and day.
The rate of severe hypoglycemia episodes (≤50 mg/dL)
was <1 %, with no clinical repercussions. Group B
showed the greater frequency of moderate hypoglycemia
(50–80 mg/dL).
No significant differences in GV were observed
between patients receiving the study diabetes-specific
formula and those given the control diabetes-specific
formula. Both specific formulas achieved a reduction in
glycemic variability relative to the standard formula in
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the first week of ICU stay (GLI p <0.05, SD p <0.01,
CV p <0.001). Over the 28 days of follow- up, re-
ductions were also produced in GLI (p <0.05) and
SD (p <0.01).
Plasma levels of cholesterol, triglycerides, albumin
and prealbumin were similar across the three treatment
groups.
Infection control
Infectious complications recorded in the study partici-
pants are provided in Table 5. Numbers of infected pa-
tients and incidences of any infection per 100 days of
treatment were lower in the study group, but not signifi-
cantly (p = 0.54 and p = 0.51 respectively). Catheter-
associated bloodstream infection, primary bloodstream
6280 patients on artificial nutritional support
assessed for eligibility
4820 excluded due to
TPN, SPN or EN + PN
1460 eligible for EN
1304 ineligible
733 expected EN <5 days
27 immunosuppressive treatment
72 life expectancy <48 h
37 participation declined
94 dyslipidemia treatment
38 previous cardiac arrest




74 treatment with steroids
13 unknown reasons
159 underwent randomization
2 incorrect randomization 1 group A, 1 group C
157 underwent analysis
Group A               Group B             Group C   
n=52 n= 53 n=52
6a 5b 4c lost post randomization
(<5 days of EN)
Group A               Group B               Group C         Intention-to-treat analysis
n=52    n=53                    n=52      
Fig. 1 Enrollment, randomization and follow-up of the study participants. TPN total parenteral nutrition, SPN supplementary parenteral nutrition,
EN enteral nutrition. a Three deaths, one withdrawal by patient, one withdrawal by doctor, one change of diet. b Two deaths, one withdrawal by
doctor, one change of diet, one infusion interrupted >48 h. cTwo deaths, one change of diet, one infusion interrupted >48 hours
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Table 3 Nutrients received
GROUP A GROUP B GROUP C p value
(n = 52) (n = 53) (n = 52)
Volume ratio (%) 79.8 (13.4) 81.1 (17) 82.4 (15) 0.71
Total calories received (kcal/day) 1349 (323) 1385 (454) 1423 (383) 0.17
(kcal/kg/day) 22.2 (4.1) 21.7 (4.8) 21.3 (3.8)
Protein (g/day) 76.8 (18.4) 69.2 (23.2) 71.1 (19.1) 0.11
(g/kg/day) 1.26 (0.32) 1.21 (0.27) 1.23 (0.18)
Carbohydrates (g/day) 110.6 (25.8) 151.3 (50.7)*a 106.1 (28.6) <0.001*
(g/kg/day) 1.6 (0.18) 2.1 (0.26) 1.5 (0.19)
Fat (g/day) 59.3 (16.4) 52.4 (17.5)*b 77.4 (20.8)*c <0.01*b
(g/kg/day) 0.8 (0.12) 0.71 (0.17) 0.96 (0.22) <0.001*c
Fiber (g/day) 19.1 (5.8) 13.4 (4.9)a* 15.7 (5.5)*d <0.01*d
(g/kg/day) 0.26 (0.09) 0.16 (0.05) 0.2 (0.06) <0.001*a
Values are provided as means (SD). Asterisks indicate statistical significance
aDifference group B vs. groups A and C
bDifference group A vs. group B
cDifference group C vs. groups A and B
dDifference group A vs. group C
Table 4 Variables related to glycemic control
GROUP A GROUP B GROUP C p value
(n = 52) (n = 53) (n = 52)
Administered insulin (IU/day) 19.1 (13.1) 23.7 (40.1)*a 20.3 (30.1) <0.05*
Plasma glucose level (mg/dL) 138.6 (39.1) 146.1 (49.9)*a 143.9 (45.9) <0.01*
Capillary glucose level (mg/dL) 146.1 (45.8) 155.3 (63.6)*a 150.1 (41.9)*b,c <0.001*a
<0.01*b,c
Mean capillary glycemia on ICU day 1 (mg/dL) 147.5 (40.2) 160 (55.5)*d 145.6 (46.6) <0.01*
Peak glucose level (mg/dL) 181.3 (52) 193.6 (74.6) 191.3 (65.8) 0.68
Number of capillary glycemia measurements 3605 3523 3557 0.57
Number of measurements per patient/day 5.7 (3.4) 5.81 (3.2) 5.46 (2.9) 0.56
Percentage of controls on 80–150 mg/dL 59 % 57.6 % 59.59 % 0.82
Hypoglycemia (50–80 mg/dL) 53 (1.48 %) 127 (3.63 %)*d 44 (1.25 %) <0.05*
Hypoglycemia (<50 mg/dL) - 4 (0.11 %) 1 (0.02 %) 0.32
Capillary glucose SD 45.83 63.67*d 41.98 <0.01*
Glycemic lability index (ICU days 1–28) 0.58 (0.2–1.4) 0.71 (0.3–1.9)*d 0.44 (0.2–1.2) <0.05*
Glycemic lability index (ICU days 1–7) 0.27 (0.1–0.7) 0.6 (0.2–1.2)*d 0.27 (0.2–0.8) <0.05*
Glycemic variability SD (mg/dL) (ICU days 1–28) 33.6 (18.4) 49.1 (21.5)*a 41.1 (9.3) <0.01*
Glycemic variability SD (mg/dL) (ICU days 1–7) 43.2 (4.9) 68.5 (13.5)*d 42.5 (2.7) <0.01*
Glycemic CV (%) (ICU days 1–28) 27.9 (5.8) 32.4 (11.2) 27.8 (5.2) 0.13
Glycemic CV (%) (ICU days 1–7) 28.3 (1.9) 42.6 (8.2)*d 28.4 (2.1) <0.001*
Values are provided as mean (SD) and percentages (%). Asterisks indicate statistical significance
IU, international units, ICU intensive care unit, SD, standard deviation, CV coefficient of variation
aDifference group A vs. group B
bDifference group B vs. group C
cDifference group A vs. group C
dDifference group B vs. groups A and C
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infection and urinary tract infection did not vary across
the groups. Rates of ventilator-associated tracheobron-
chitis and pneumonia per 1000 days of MV were signifi-
cantly lower for the study (p <0.01 and p <0.05
respectively) and control (p <0.01) diabetes formulas
than the standard formula. No significant differences in
infectious complications were produced in patients
randomized to receive the study or control diabetes
formulas.
We also examined the relationship between glycemic
variability and acquired infections (Table 6). Thus, the
incidence of tracheobronchitis per 1000 days of MV
showed high significant correlation with glycemic CV
for the first week of ICU stay (r = 0.997; p = 0.04). This
variable also showed high correlation, albeit without
significance, with GLI recorded over 28 days (r = 0.989;
p = 0.09) and 1 week (r = 0.997; p = 0.05) of follow-up,
and with SD for 1 week (r = 0.995; p = 0.06) and CV for
28 days (r = 0.995; p = 0.06) of follow-up. The incidence
of ventilator-associated pneumonia / 1000 days of MV
only showed high correlation but without significance
with the MCG recorded in the first ICU stay (r = 0.988;
p = 0.09).
Other nutritional and clinical outcomes
Diet tolerance was good in all three treatment groups.
Only in 11 patients (7 %) did EN have to be interrupted
for more than 48 h due to gastrointestinal complications.
The complications observed were abdominal distension
in one patient (group B), diarrhea in six patients (two
group A, one group B and three group C) and high GRV
in four patients (one group A, two group B and one
group C). The remaining clinical outcomes are shown in
Table 7. No significant differences among groups were
produced in the number of days on insulin treatment or
on enteral nutrition, number of days on MV, ICU and
Table 5 Acquired infectious complications
GROUP A GROUP B GROUP C p value
(n = 52) (n = 53) (n = 52)
Number of infected patients 18/52 (34.6 %) 23/53 (43.4 %) 23/52 (44.2 %) 0.54
Odds ratio 1.4 (0.6–3.1)a 1.03 (0.4–2.2)c
1.4 (0.6–3.3)b
Infectious complication incidence rate / % treatment days 22/546 (4.03) 24/470 (5.11) 24/505 (4.75) 0.51
Catheter-related bloodstream infection 1/52 (1.92 %) 1/53 (1.89 %) 2/52 (3.85 %) 0.53
Primary bloodstream infection 3/52 (5.77 %) 1/53 (1.89 %) 3/52 (5.77 %) 0.25
UTI 1/52 (1.92 %) 1/53 (1.89 %) 1/52 (1.92 %) 1.00
Tracheobronchitis incidence rate / 1000 ventilator days 7/460 (15.2)*a 10/392 (25.5) 7/424 (16.5)*c <0.01*
VAP incidence rate / 1000 ventilator days 8/460 (17.3)*a 10/392 (25.5) 6/424 (14.1)*c <0.05*a
< 0.01*c
Values are provided as percentages (%) and incidence rate. Asterisks indicate statistical significance
UTI urinary tract infection, VAP ventilator-associated pneumonia
aDifference group A vs. group B
bDifference group A vs. group C
cDifference group B vs. group C
Table 6 Relationship between glycemic control and infectious complications determined through Pearson linear correlation (r)
Pneumonia / 1000 ventilator days p value Tracheobronchitis / 1000 ventilator days p value
Mean plasma glucose level r = 0.512 0.65 r = 0.778 0.43
Mean capillary glucose level r = 0.749 0.46 r = 0.933 0.23
Administered insulin r = 0.863 0.33 r = 0.985 0.11
Mean capillary glucose on day 1 r = 0.988 0.09 r = 0.980 0.12
Variability (GLI) days 1–28 r = 0.978 0.13 r = 0.989 0.09
Variability (GLI) days 1–7 r = 0.962 0.17 r = 0.997 0.05
Variability (SD) days 1–28 r = 0.713 0.49 r = 0.912 0.26
Variability (SD) days 1–7 r = 0.969 0.16 r = 0.995 0.06
Coefficient of glycemic variation days 1–28 r = 0.967 0.16 r = 0.995 0.06
Coefficient of glycemic variation days 1–7 r = 0.961 0.17 r = 0.997 0.04
GLI glycemic lability index, SD standard deviation
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hospital stay, and mortality at 28 days and at 6 months.
Figure S1 in Additional file 3 provides the numbers of
patients remaining in the study during the 28-day course
of follow-up.
Discussion
This study shows that a diabetes-specific high-protein
EN formula containing MUFA, slowly absorbed carbohy-
drates and omega-3 PUFA enriched with EPA, DHA and
fiber gives rise to better glycemic homeostasis than a
standard high-protein formula and may also reduce the
risk of acquired infections in ICU patients.
When comparing the diabetes-specific study formula
(A) with a widely used diabetes-specific formula of dif-
ferent composition (C), the only significant difference
found was a lower mean capillary blood glucose level in
patients given the study formula.
The similar 28-day and 6-month mortality rates re-
corded for the three treatment groups could be related
to an insufficient sample size for comparing these end-
points. No effects of the different formulas were pro-
duced on insulin resistance or sensitivity determined
using the HOMA2 calculator.
Glycemic control
Continuous insulin infusion protocols help to main-
tain plasma glucose levels within recommended
ranges [14, 15, 18–20]. However, consistent with our
findings, numerous studies have shown that insulin re-
quirements and plasma and capillary blood glucose levels
can be reduced using a diabetes-specific EN formula as an
adjuvant to insulin [22, 25, 27, 29, 30] (Table 4). It there-
fore seems that the composition of these formulas, both in
quantitative terms (smaller percentages of carbohydrates
and higher fat percentages) and qualitative terms
(including modified carbohydrates and MUFA, EPA and
DHA), helps reduce insulin requirements, and this also
reduces the risk of hypoglycemia. No prior studies in crit-
ical patients have compared enteral feeding formulas with
similar protein and fat contents but different carbohydrate
sources and levels such that we cannot attribute the better
blood glucose control observed here to the carbohydrate
supply provided by the formula. Notwithstanding, recent
clinical practice guidelines [23, 24] do not recommend the
use of this type of formula and indicate a need for further
studies.
For some years, GV has been associated with outcome
in the critically ill patient. Thus, in a cohort of 7049 crit-
ical patients, Egi et al. [8] observed a greater GV in pa-
tients who died than in survivors. Similarly, Hermanides
et al. [9], in 5728 critical patients, found a significant re-
lationship between GV, measured as mean absolute glu-
cose, and the likelihood of ICU death. In addition,
Krinsley et al. [10], in an international, multicenter co-
hort study conducted in 44,964 patients, noted that
greater GV was independently associated with increased
mortality in critical patients with no prior diabetes.
These studies on GV, however, failed to address the
nutritional support or, in many cases, the amount of in-
sulin administered to the patients. Thus, it is worth ask-
ing what influence these diabetes-specific formulas
could have in controlling both hyperglycemia and GV.
Alish et al. [12] reported lower GV based on the mean
amplitude of glycemic excursions (MAGE) in noncriti-
cally ill patients with diabetes who were administered a
diabetes-specific formula than in those administered a
Table 7 Other clinical outcomes
GROUP A GROUP B GROUP C p value
(n = 52) (n = 53) (n = 52)
Days on insulin treatment 7.1 (2.8) 7.9 (3.2) 7.7 (3.9) 0.41
Days on enteral nutrition 10.5 (7.1) 8.8 (6.7) 9.7 (7.4) 0.39
Days on mechanical ventilation 7 (4–13) 6 (2–11) 6 (3–12) 0.53
ICU stay (days) 13 (9–20) 12 (7–21) 11.5 (7.5–18) 0.42
Hospital stay (days) 27 (18–50) 25 (17–51) 30.5 (14–46.5) 0.98
28-day mortality (N and %) 11 (21.1 %) 10 (18.87) 13 (25 %) 0.73
6-month mortality (N and %) 16 (30.7 %) 20 (37.74) 18 (34.62) 0.71
Δ SOFA −0.37 −0.28 −0.33 0.42
Δ Triglycerides +0.02 −0.21 +0.12 0.18
Δ HOMA2 IR −0.17 −0.01 −0.22 0.76
Δ HOMA2 % S +0.17 +0.09 +0.12 0.89
Δ HOMA2 β-cell +0.21 +0.12 +0.09 0.81
Values are provided as mean (SD), median (Q1-Q3) and percentages (%)
ICU intensive care unit, N number, Δ delta baseline-ICU discharge, SOFA Sequential Organ Failure Assessment, HOMA2, Homeostasis Model Assessment, IR insulin
resistance, %S insulin sensitivity, %B beta cell function
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standard formula. These results are in agreement with
those of our study (Table 4) indicating similarly lower
glucose variability for the diabetes-specific study and
control formulas versus the standard formula, both in
the first week of ICU stay and for 28 days of follow-up.
In the first 7 days of ICU stay, stress hypermetabolism is
at its maximum and its adequate control can impact
short-term outcomes in critically ill patients. In our pa-
tients, greatest differences among treatment groups were
detected in MCG on the first ICU day and in GV and
CV during the first ICU week. Given the important role
of GV in critically ill patient outcomes, we recommend
the use of such specific formulas in hyperglycemic ICU
patients, at least during the first week of ICU stay.
Infection control
A relationship between hyperglycemia and infection has
been established in several populations of critically ill pa-
tients [39–41]. In a meta-analysis of data from 29 random-
ized, controlled trials including 8432 patients, fewer septic
complications were observed in patients subjected to strict
glycemic control [18]. Similarly, Van den Berghe et al. [16]
noticed fewer infections in surgical patients in whom a
tight glycemic control protocol had been followed. How-
ever, these findings were not confirmed in a subsequent
study in medical patients [42], in the NICE-SUGAR study
[14] or in a subsequent meta-analysis [15].
In our study, fewer ICU-acquired infections were ob-
served in patients on both diabetes-specific high-protein
formulas than those given the standard high-protein for-
mula (Table 5). The differences in insulin needs and in
plasma and capillary glycemia between these groups
could only partially explain this reduction. We also ana-
lyzed (Table 6) the relationship between glycemic con-
trol and any significant infections identified in the group
comparisons. Thus, as stated in the results section, high
significant correlation (r >0.9) with tracheobronchitis ep-
isodes per 1000 days of MV was detected for glycemic
CV in the first week of ICU stay and a trend toward
significance was noted for the other glycemia variability
parameters. This correlation with infection was not
observed for the other variables such as the amount of
insulin administered or capillary blood and plasma glu-
cose levels.
As far as we know, no similar data exist in the medical
literature linking rates of infectious complications to the
administration of diabetes-specific formulas in critically
ill patients. In a retrospective study of 2782 patients ad-
mitted to a medical-surgical ICU, Donati et al. [11] were
the first to report close correlation between glycemic
variability (GLI, SD, CV and MAGE) and acquired infec-
tions in diabetic and nondiabetic patients, with higher
discriminative values observed for GLI and CV. Our
findings also point to this correlation though since it
was not a primary endpoint this correlation needs to be
confirmed.
Many retrospective studies have revealed a relation-
ship between high glycemic variability and poor out-
comes in critically ill patients. To date, however, there
are no sufficiently established standardized methods to
control such variability. We could nevertheless speculate
that, by reducing insulin requirements and plasma and
capillary glucose levels, the use of specific formulas for
diabetes would be useful for this purpose. Further pro-
spective, randomized studies in large patient series are
warranted to confirm this relationship and its potential
therapeutic consequences.
Strengths and limitations
As strengths of this study, we should mention the idea
that glycemic control can be modified using specific
enteral nutrients in the critically ill patient; also the
external validity of the methodology (prospective,
blind-randomized, multicenter) and the generalizability
of results. Its main limitations are that it was an open-
label study, so some of its results (especially effects on
infectious complications) need to be considered with
caution. The use of capillary samples for blood glucose
instead of arterial samples and use of the point-of-care
glucose meter could be considered a further limitation.
Consensus recommendations published in 2013 [43]
highlight the need to obtain arterial rather than capil-
lary blood samples. This was selected as the standard-
ized method by the researchers at the nine hospitals
given it was logistically nonviable to collect arterial
blood samples at the frequency necessary at two of the
centers. However, regardless of the greater or lesser
reliability of absolute glycemia values, the use of capil-
lary samples should not affect the comparisons made
between the three groups of patients. As a final limita-
tion, the sample size precluded reaching conclusions on
outcome measures (such as mortality) other than those
related to glycemic or infection control.
Although the components of a diabetic-specific formula
are important, no marked differences were observed in
the impacts of the two such formulas examined here.
Thus, to confirm the present findings and further examine
EN effects on glycemic variability and mortality, we
recommend comparing the latest-generation diabetes-
specific formula with a standard formula in a multicenter,
double-blind trial in a large patient sample.
Conclusions
The use of a high-protein diabetes-specific EN formula
in hyperglycemic critically ill patients on mechanical
ventilation leads to lower insulin requirements, reduces
plasma and capillary blood glucose levels and glycemic
variability, and could also reduce the risks of ICU-
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acquired ventilator-associated pneumonia and tracheo-
bronchitis when compared with that of a standard high-
protein formula. Similar findings were obtained for the
use of another diabetes-specific formula of different
composition.
Our results highlight the need for double-blind studies
with glycemic variability as the primary endpoint in large
critically ill patient populations to address the impacts of
these enteral nutrition formulas on outcomes such as
acquired infections, hospital stay and short- and medium-
term mortality.
Key messages
 Few studies have explored the possible benefits of
diabetes-specific EN formulas in terms of controlling
hyperglycemia, glucose variability and acquired
infectious complications.
 In our study, compared with a high-protein standard
EN formula, a high-protein diabetes-specific formula
reduced insulin requirements, glucose variability,
and plasma and capillary glycemia in mechanically
ventilated, hyperglycemic ICU patients.
 Our results also point to beneficial impacts of such
a formula on ICU-acquired infections such as venti-
lator-associated tracheobronchitis and pneumonia.
However, further efforts in the form of larger
clinical trials are required to assess the capacity of
these formulas to reduce the risk of acquired
infections in these patients.
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